Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The company operates a chain of mid-sized multi-speciality hospitals
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
